Abstract
In this society, Alzheimer's disease represents a significant public health concern. Nevertheless, the market offers only two FDA-approved drugs, which are capable of only partially inhibiting the symptoms. It is imperative that both patients and researchers are made aware of the mechanism by which AD is triggered and the fundamental logic underlying the action of each drug. This should include an understanding of how the drug reacts with the body and the ingredients that it contains. This section primarily discusses the therapeutic options for Alzheimer's disease, encompassing both the drugs and mechanisms that are currently available on the market and those that have not yet been approved but are theoretically feasible. This passage will introduce a number of potential treatments for Alzheimer's disease, including Chinese patent medicine, acetylcholinesterase inhibitors, NMDA receptor antagonists, Aduhelm, Leqembi, anti-amyloid therapies and A immunotherapies. Despite the existence of these treatments for many years, it is still not possible to cure Alzheimer's disease completely or to delay or prevent its progression. This passage aims to provide insights into the future direction of pharmaceutical research and the selection of appropriate medications
Published Version
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call